Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6871 to 6885 of 7691 results

  1. ALXN1840 for treating Wilson disease TS ID 9950

    In development [GID-TA11449] Expected publication date: TBC

  2. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    In development [GID-TA10822] Expected publication date: TBC

  3. Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]

    Discontinued [GID-TA10830]

  4. Etrolizumab for previously treated moderately to severely active Crohn's disease [ID3965]

    Discontinued [GID-TA10870]

  5. Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]

    Discontinued [GID-TA10963]

  6. Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

    Discontinued [GID-TA10811]

  7. Housing: planning to improve health and wellbeing

    Discontinued [GID-NG10053]

  8. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development [GID-TA10489] Expected publication date: TBC

  9. Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

    Discontinued [GID-TA10495]

  10. Workplace health - older employees

    Discontinued [GID-PHG59]

  11. DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

    Discontinued [GID-MT536]

  12. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued [GID-TAG393]